/MYOV

MYOV Stock - Myovant Sciences Ltd.

Q: What is the analyst price target for MYOV?

Analyst price target information is not currently available for MYOV.

Q: What is MYOV's market cap?

Market capitalization information is not currently available for MYOV.

Healthcare|Biotechnology|NYSE

$26.98-0.04%

$0.01 (-0.04%) • Mar 9

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $29.68

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MYOV

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta2.15

52W High$27.06

52W Low$7.67

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$230.97M	$59.32M	N/A	N/A	N/A
Gross Profit	$179.42M	$57.35M	N/A	N/A	N/A
Gross Margin	77.7%	96.7%	N/A	N/A	N/A
Operating Income	$-187,346,000	$-260,784,000	$-270,714,000	$-264,826,000	$-141,063,000
Net Income	$-205,981,000	$-255,134,000	$-288,989,000	$-273,551,000	$-143,255,000
Net Margin	-89.2%	-430.1%	N/A	N/A	N/A
EPS	$-2.22	$-2.83	$-3.37	$-4.09	$-2.41

Company Overview

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

$23

Average Target

↓ 14.8% Downside

Now

$23

Low

$23

Average

$23

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
October 26th 2022	Evercore ISI	Downgrade	In-line	-
August 9th 2022	SVB Leerink	Upgrade	Outperform	$23← $12

Earnings History & Surprises

MYOV

Beat Rate

44%

Last 18 quarters

Avg Surprise

-2.4%

EPS vs Estimate

Beats / Misses

8/10

Last 12 quarters

Latest EPS

$-0.59

Q1 2023

EPS Surprise History

Q2 21

+10.1%

$-0.89vs$-0.99

Q3 21

-97.1%

$-0.67vs$-0.34

Q4 21

+39.5%

$-0.23vs$-0.38

Q1 22

-11.5%

$-0.68vs$-0.61

Q2 22

-10.5%

$-0.63vs$-0.57

Q3 22

+31.3%

$-0.22vs$-0.32

Q4 22

+4.1%

$-0.47vs$-0.49

Q1 23

-25.5%

$-0.59vs$-0.47

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2023	Jul 25, 2023	$-0.51	—	—	—
Q2 2023	May 8, 2023	$-0.51	—	—	—
Q1 2023	Jan 26, 2023	$-0.47	$-0.59	-25.5%	✗ MISS
Q4 2022	Oct 26, 2022	$-0.49	$-0.47	+4.1%	✓ BEAT
Q3 2022	Jul 27, 2022	$-0.32	$-0.22	+31.3%	✓ BEAT
Q2 2022	May 10, 2022	$-0.57	$-0.63	-10.5%	✗ MISS
Q1 2022	Jan 26, 2022	$-0.61	$-0.68	-11.5%	✗ MISS
Q4 2021	Oct 26, 2021	$-0.38	$-0.23	+39.5%	✓ BEAT
Q3 2021	Jul 28, 2021	$-0.34	$-0.67	-97.1%	✗ MISS
Q2 2021	May 11, 2021	$-0.99	$-0.89	+10.1%	✓ BEAT
Q1 2021	Feb 11, 2021	$-0.85	$-0.82	+3.5%	✓ BEAT
Q4 2020	Nov 12, 2020	$-0.73	$-0.75	-2.7%	✗ MISS
Q3 2020	Aug 11, 2020	$-0.68	$-0.37	+45.6%	✓ BEAT
Q2 2020	May 18, 2020	$-0.80	$-0.73	+8.8%	✓ BEAT
Q1 2020	Feb 10, 2020	$-0.82	$-0.96	-17.1%	✗ MISS
Q4 2019	Nov 12, 2019	$-0.72	$-0.79	-9.7%	✗ MISS
Q3 2019	Aug 6, 2019	$-0.95	$-0.89	+6.3%	✓ BEAT
Q2 2019	May 24, 2019	$-1.02	$-1.07	-4.9%	✗ MISS
Q1 2019	Feb 7, 2019	$-0.98	$-1.04	-6.1%	✗ MISS
Q4 2018	Nov 8, 2018	$-0.93	$-0.99	-6.5%	✗ MISS